In a stunning reversal, AstraZeneca, the maker of the Covishield vaccine, has acknowledged rare side effects potentially linked to the jab. The British pharmaceutical giant has conceded in court documents that Covishield can trigger a condition known as Thrombosis with Thrombocytopenia Syndrome (TTS), causing blood clots and low platelet counts in some recipients.

This admission comes amidst mounting legal pressure, including a class-action lawsuit in the UK alleging that the vaccine led to fatalities and severe injuries in numerous cases. With victims seeking damages of up to £100 million, AstraZeneca‘s stance has shifted dramatically from its previous denial of a causal link between the vaccine and TTS.

The case’s first complainant, Jamie Scott, recounted his harrowing experience, claiming Covishield inflicted a permanent brain injury through a blood clot, leaving him unable to work. AstraZeneca’s acknowledgment of TTS in “very rare cases”, marks a significant departure from its earlier stance, potentially paving the way for compensation to affected individuals and their families.

However, the company continues to refute claims of vaccine defectiveness and overstatement of efficacy. As scrutiny intensifies, AstraZeneca’s admission raises questions about vaccine safety and accountability, with broader implications for public health policy and the ongoing battle against COVID-19.

Stay tuned with ehealth as this story unfolds, reshaping the landscape of vaccine litigation and prompting renewed scrutiny of Covishield’s safety profile.

Like 6

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!